Antony Barnett,investigations editor
Sunday May 28, 2006
The Observer
119 Farringdon Road
London EC1R 3ER
United Kingdom
Tel:00-44-207-278-2332
E-mail: [EMAIL PROTECTED]
Dr.Tonmoy Sharma is the son of Mr. Phani Sharma is a businessman and a member
of the Congress party in Guwahati, is in serious fraud business in UK involving
millions of pounds. His whole family are in the film business. His sister,
Sanchayita Sharma and sometimes known as Sanchayita Goswami made a documentary
recently for the film 'Passage' which was screened at the Cannes by the same
fraud money. Dr.Tonmoy Sharma is currently hiding in America.His sister-in-law
is Bobbeeta Sharma is the current Chairspokeperson for the Assam Pradesh
Congress party and is also the chairperson of the Assam Film Finance
Development Corporation Ltd is involved in this fraud scam too. Bobbeeta Sharma
has used the same fraud money to produce lots of TV serials and films for the
film industry in Assam.
A professor who taught at one of Britain's most prestigious medical institutes
while appearing regularly as an expert on the BBC online, has been accused of
being a fraud and has a warrant out for his arrest. Tonmoy Sharma, who was a
senior lecturer at the Institute of Psychiatry in London, is accused of
deceiving the NHS and some of the world's largest drug firms, and lying about
his academic credentials.
Sharma, who denies all the claims, is being accused by the pharmaceutical
companies' trade body of taking part in wide-ranging research fraud involving
tests of powerful drugs on schizophrenic patients.
He says the firms have targeted him as 'a scapegoat' to cover their own
failures and protect people in the industry. He also believes he is the victim
of academic rivals jealous of his success.
The high-profile dispute is to come before the General Medical Council (GMC) in
September. It will be embarrassing for the medical and academic establishments
and raise questions about how UK drug trials are conducted.
At one stage Sharma was offered the chair of psychiatry at University College
London, and over a period of years from 1996 he was paid hundreds of thousands
of pounds by drugs giants such as Novartis and
Sanofi to conduct trials of anti-psychotic drugs on patients with schizophrenia
and Alzheimer's disease.
The firms belong to the Association of the British Pharmaceutical Industry
(ABPI), which will ask the GMC to find him guilty of professional misconduct.
The association is expected to allege that he failed to obtain proper approval
from ethical committees to conduct a number of major studies. These approvals
are a vital component in any trial to protect the patients taking part.
The association will also claim Sharma used the same patients as subjects for a
number of different studies without telling the drug firms, which had each paid
him six-figure sums for what they believed to be unique research. Sharma will
deny any improper conduct.
He worked as a consultant psychiatrist for the South London and Maudsley NHS.
Trust and recruited patients in Kent and parts of the capital for the research.
His position at the institute helped him secure funding worth close to £1m from
five drug firms. Most of the money was channelled not through the institute but
a private firm he set up called Psychmed. Sharma claims the institute knew
about this arrangement and had approved it.
The fraud allegations against him surfaced in 2001 when Dr Catherine Baxter, a
medical adviser to Sanofi, uncovered alleged financial irregularities
surrounding a £250,000 contract it had awarded Sharma.
The firm had asked him to conduct a study comparing the effectiveness of its
drug Amisulpride with that of a treatment from a rival company, Eli Lilly.
Although Baxter believed the study was to be undertaken at the institute, she
became alarmed about a Sanofi cheque for £65,000 that had been paid to Sharma's
company. She also became 'extremely concerned' that Sharma appeared not to have
received proper ethical approval for the study.
Sanofi hired private investigators to check Sharma's research activities. The
inquiries were led by Peter Jay, a former Metropolitan Police detective chief
inspector. When Sharma found out about Jay's investigation he sued him for
defamation, claiming the inquiry had unfairly destroyed his reputation.
Sharma dropped the case last March for what he said were financial reasons.
Among the allegations that surfaced in the High Court before the case ended was
a claim that Sharma attempted to get data changed in one study to show that the
drug risperidone worked better against schizophrenia than rival conventional
treatments.
He insisted, however, that he had 'never sought to pressurise anyone to
manipulate the data'.
He was also accused of lying about his academic background. Sharma, who
qualified as a doctor in India, describes himself as a professor in the media
and in promotional literature for his companies. He has claimed he was entitled
to do so because he was a 'visiting professor of psychiatry at the University
of Pittsburgh, Pennsylvania, USA'.
Yet Theresa Ratti, executive administrator of the university's School of
Medicine, has denied this. In a letter, she wrote: 'Dr Sharma currently does
not hold the appointment of visiting professor of psychiatry at the university,
nor has he held such a title in the past.'
In the libel case, Jay said Sharma asked Novartis for a free supply of the drug
Clozaril for a study, but allegedly sold it to a hospital pharmacy for tens of
thousands of pounds.
These claims have led to charges of deception being brought against Sharma by
the government health watchdog, the Medicines and Healthcare Products
Regulatory Agency (MHPRA). He failed to answer a summons to appear at Bow
Street court in London last February, and a warrant was later issued for his
arrest.
Sharma, speaking this weekend from India where he said he was caring for his
sick father, claimed he had not been aware of the charge nor of the court
hearing. He would be happy to come back to Britain to defend himself. There was
a legitimate explanation for the transaction from which he made no personal
gain.
Sharma said he was looking forward to the GMC hearing as an opportunity to tell
his side of the story publicly and prove the fault lay with the drug companies.
'When these allegations first surfaced the Institute of Psychiatry investigated
them and exonerated me of any wrongdoing,' he said. He claimed Sanofi knew this
but decided to blame him for mistakes in its administrative and research
procedures. 'Everything spiralled from there,' he said.
Asked about his academic background, Sharma said he has a letter to prove he
was invited by a psychiatry professor at Pittsburgh Uto give lectures there as
a 'visiting professor'.
The Institute of Psychiatry declined to comment. The ABPI confirmed it was
taking Sharma to the GMC but refused to discuss any details.
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/assamonline/
<*> Your email settings:
Individual Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/assamonline/join
(Yahoo! ID required)
<*> To change settings via email:
mailto:[EMAIL PROTECTED]
mailto:[EMAIL PROTECTED]
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
